Rahul Ravilla

1.7k total citations · 1 hit paper
17 papers, 1.3k citations indexed

About

Rahul Ravilla is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Rahul Ravilla has authored 17 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Rahul Ravilla's work include Cancer Immunotherapy and Biomarkers (6 papers), Melanoma and MAPK Pathways (5 papers) and Renal cell carcinoma treatment (4 papers). Rahul Ravilla is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Melanoma and MAPK Pathways (5 papers) and Renal cell carcinoma treatment (4 papers). Rahul Ravilla collaborates with scholars based in United States, Australia and United Kingdom. Rahul Ravilla's co-authors include Asween Marco, Maria Theresa E. Montales, Shashank Kraleti, Appalanaidu Sasapu, Aditya Chada, Naveen Patil, Kevin Kuriakose, Chitharanjan Duvoor, Vijaya Sena Dendi and Arun Chaudhury and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Annals of Oncology.

In The Last Decade

Rahul Ravilla

16 papers receiving 1.3k citations

Hit Papers

Clinical Review of Antidiabetic Drugs: Implications for T... 2017 2026 2020 2023 2017 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management
    2017 1.1k citations Arun Chaudhury, Chitharanjan Duvoor et al. Frontiers in Endocrinology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rahul Ravilla United States 7 594 423 170 166 146 17 1.3k
Maria Theresa E. Montales United States 11 609 1.0× 532 1.3× 147 0.9× 154 0.9× 160 1.1× 16 1.4k
Jayadev Raju Canada 20 500 0.8× 717 1.7× 111 0.7× 100 0.6× 253 1.7× 44 1.7k
Kevin Kuriakose United States 6 608 1.0× 416 1.0× 45 0.3× 135 0.8× 148 1.0× 15 1.3k
Adel Abdel‐Moneim Egypt 17 418 0.7× 312 0.7× 58 0.3× 135 0.8× 132 0.9× 48 1.3k
Ghada M. Suddеk Egypt 28 176 0.3× 546 1.3× 134 0.8× 167 1.0× 185 1.3× 77 1.8k
Antony Stalin China 21 243 0.4× 479 1.1× 119 0.7× 71 0.4× 277 1.9× 97 1.3k
Cuihua Jiang China 26 253 0.4× 829 2.0× 122 0.7× 83 0.5× 379 2.6× 91 1.9k
Feihua Wu China 24 266 0.4× 622 1.5× 125 0.7× 107 0.6× 243 1.7× 63 1.5k
Appalanaidu Sasapu United States 5 594 1.0× 353 0.8× 40 0.2× 127 0.8× 146 1.0× 23 1.2k
Aditya Chada United States 5 594 1.0× 346 0.8× 33 0.2× 123 0.7× 146 1.0× 10 1.1k

Countries citing papers authored by Rahul Ravilla

Since Specialization
Citations

This map shows the geographic impact of Rahul Ravilla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rahul Ravilla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rahul Ravilla more than expected).

Fields of papers citing papers by Rahul Ravilla

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rahul Ravilla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rahul Ravilla. The network helps show where Rahul Ravilla may publish in the future.

Co-authorship network of co-authors of Rahul Ravilla

This figure shows the co-authorship network connecting the top 25 collaborators of Rahul Ravilla. A scholar is included among the top collaborators of Rahul Ravilla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rahul Ravilla. Rahul Ravilla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Shah, Neil J., Rahul Ravilla, Karen Todoroff, et al.. (2025). Real-world treatment pattern and clinical outcomes among patients with metastatic renal cell (mRCC) carcinoma post PD-1/PD-L1 immuno-oncology (IO) therapies.. Journal of Clinical Oncology. 43(5_suppl). 501–501.
2.
Agarwal, Neeraj, James Brugarolas, Pooja Ghatalia, et al.. (2024). Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma. Annals of Oncology. 35(12). 1148–1156. 6 indexed citations
3.
Atkins, Michael B., Pooja Ghatalia, Jaime R. Merchan, et al.. (2024). Belzutifan in patients with advanced clear cell renal cellcarcinoma (ccRCC): Subgroup analysis of the phase 2 LITESPARK-013 study.. Journal of Clinical Oncology. 42(16_suppl). 4534–4534. 1 indexed citations
4.
Brugarolas, James, Pooja Ghatalia, S. George, et al.. (2023). 1881O Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study. Annals of Oncology. 34. S1011–S1011. 4 indexed citations
5.
Sandhu, Shahneen, Geoffrey Gotto, Francisco Vera-Badillo, et al.. (2023). 1835P A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC). Annals of Oncology. 34. S993–S993. 2 indexed citations
6.
Zibelman, Matthew R., Michael A. Carducci, Yasser Ged, et al.. (2022). A phase I/II study of nivolumab and axitinib in patients with advanced renal cell carcinoma.. Journal of Clinical Oncology. 40(6_suppl). 291–291. 1 indexed citations
7.
Westaby, Daniel, Rahul Ravilla, Maria D. Fenor de la Maza, et al.. (2021). Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer. American Society of Clinical Oncology Educational Book. 41(41). e190–e202. 15 indexed citations
8.
Ravilla, Rahul, et al.. (2020). Immunotherapy Outcomes in Advanced Melanoma in Relation to Age. The Permanente Journal. 24(2). 10 indexed citations
9.
Ravilla, Rahul, Hannah Coleman, Cheryl‐Emiliane T. Chow, et al.. (2019). Cervical Microbiome and Response to a Human Papillomavirus Therapeutic Vaccine for Treating High-Grade Cervical Squamous Intraepithelial Lesion. Integrative Cancer Therapies. 18. 1871111495–1871111495. 13 indexed citations
10.
Ravilla, Rahul, et al.. (2018). Outcomes of immunotherapy in advanced melanoma in relation to age.. Journal of Clinical Oncology. 36(5_suppl). 187–187. 5 indexed citations
11.
Ravilla, Rahul, Hannah Coleman, Luisa Chan, et al.. (2018). Cervical microbiome role in outcomes of therapeutic HPV vaccination for cervical intraepithelial neoplasia.. Journal of Clinical Oncology. 36(15_suppl). 3099–3099. 3 indexed citations
12.
Ravilla, Rahul, et al.. (2017). Pembrolizumab-Induced Pancytopenia: A Case Report. The Permanente Journal. 21(3). 17–4. 25 indexed citations
13.
Chaudhury, Arun, Chitharanjan Duvoor, Vijaya Sena Dendi, et al.. (2017). Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. Frontiers in Endocrinology. 8. 6–6. 1091 indexed citations breakdown →
14.
Firwana, Belal, Rahul Ravilla, Issam Makhoul, et al.. (2017). Do checkpoint inhibitors rely on gut microbiota to fight cancer?. Journal of Oncology Pharmacy Practice. 24(6). 468–472. 3 indexed citations
15.
Hinduja, Archana, Kaustubh Limaye, Rahul Ravilla, et al.. (2016). Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy—Results of a Case Control Study. PLoS ONE. 11(11). e0166627–e0166627. 6 indexed citations
16.
Firwana, Belal, et al.. (2016). Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. Journal of Oncology Pharmacy Practice. 23(8). 620–624. 72 indexed citations
17.
Abdallah, Al‐Ola, Aline Herlopian, Rahul Ravilla, et al.. (2015). Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature. Journal of Oncology Pharmacy Practice. 22(3). 537–542. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maria Theresa E. Montales Breakdown of academic impact, for papers by Jayadev Raju Breakdown of academic impact, for papers by Kevin Kuriakose Breakdown of academic impact, for papers by Adel Abdel‐Moneim Breakdown of academic impact, for papers by Ghada M. Suddеk Breakdown of academic impact, for papers by Antony Stalin Breakdown of academic impact, for papers by Cuihua Jiang Breakdown of academic impact, for papers by Feihua Wu Breakdown of academic impact, for papers by Appalanaidu Sasapu Breakdown of academic impact, for papers by Aditya Chada
Rankless by CCL
2026